Abstract:Abstract BACKGROUND Effectiveness and safety of Dual biologic therapy (DBT) or in combination with small molecules for treatment of refractory cases of inflammatory bowel diseases (IBD) has been studied previously. In this systematic review and meta-analysis (SRMA), our aim was to update prior SRMA by Alayo et al including newer studies and randomized clinical trials Explorer and VEGA and newer endpoints including corticosteroid free remission rates, need for surgeries, and effectiveness based on IBD subtype. METHODS We conducted a systematic literature search using Clinical trials.gov, Cochrane Library, Embase, Ovid Medline, PubMed Medline, Scopus and Web of Science, identifying additional relevant studies published until January 19, 2023. Random-effects inverse variance model was used to combine the proportions of patients who achieved response/remission or developed AEs to obtain pooled estimates (primary outcomes). RESULTS A total of 1184 citations were identified through the database searches, of which 360 duplicates and 755 unsuitable studies were excluded following title/abstract screening. Then, the full-texts of the remaining 69 articles were retrieved for further investigation. Of these, 59 were excluded, leaving 10 additional eligible studies since the prior systematic review. A total of 23 studies met the inclusion criteria including 13 in prior SRMA, published between 2007 and 2023. Final analysis included 531 patients who underwent 543 therapeutic trials (TTs) of 8 different combination therapies. Of these 264 (49.7%) were men men. Among combination therapies, Ustekinumab (UST) + anti-tumor necrosis factor-alpha antagonist (aTNF) had the highest pooled clinical response (81.6% [95% CI: 66.2-97.0], I2=52%, p=0.04; 9 studies, 44 TTs) and remission (Figure 1) (64.2% [95% CI: 45.2-83.1], I2=55%, p=0.03; 8 studies, 42 TTs) rates. In patients with CD, the highest pooled clinical response and remission rates pertained to UST + aTNF (91.6% [95% CI: 79.8-100.0], I2 = 19%, p=0.28; 8 studies, 29 TTs). In patients with UC, the highest pooled clinical response rate was seen with Vedolizumab (VDZ)+UST (100.0% [95% CI: 70.0-100.0], I2 = 0%, p=1.00; 4 studies, 4 TTs) and UST + aTNF (100.0% [95% CI: 73.2-100.0], I2 = 0%, p =1.00; 4 studies, 5 TTs). and while the highest pooled clinical remission rate was with VDZ + UST (75.0% [95% CI: 26.0-100.0], I2 = 63%, p=0.05; 4 studies, 4 TTs). The lowest pooled AEs rate (Figure 2) related to tofacitinib (Tofa) + VDZ (12.5% [95% CI: 2.9-22.0], I2 = 41%, p = 0.10; 8 studies, 76 TTs), followed by UST + aTNF (12.7% [95% CI: 0.0-25.8], I2=43%, p = 0.08; 9 studies, 43 TTs) and Tofa+aTNF (13.0% [95% CI: 0.8-25.3], I2=49%, p=0.08; 6 studies, 27 TTs) in patients with IBD. CONCLUSION Combining biologics or with small molecules in treatment of refractory IBD is promising and appeared to be generally safe with no major side effects. Figure 1 Clinical remission Figure 2 Adverse events

Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review

Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's disease

Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease

Adult-onset Still's disease—pathogenesis, clinical manifestations, and new treatment options

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Anakinra in the management of adult-onset still's disease: a single-center experience

[Update on Adult-Onset Still's Disease: Diagnosis, Therapy and Guideline]

A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains

Renal manifestations in adult-onset Still's disease: a systematic review

Clinical and immunological feature, therapeutic response and prognosis of adult onset Still's disease

Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

SYSTEMATIC REVIEW WITH META-ANALYSIS: SAFETY AND EFFICTIVENESS OF COMBINING BIOLOGICS AND SMALL MOLECULES IN INFLMAMMATORY BOWEL DISEASE

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis

Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials